Jan 14, 2020
Global Brain Tumor Drugs Market Expected to Exceed $3 Billion Through 2022
Jan 14, 2020
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Jan 14, 2020
ZAP Surgical Brain Tumor Treatments Commence at PLA General Hospital 301 in Beijing, China
Jan 13, 2020
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
Jan 09, 2020
American Brain Tumor Association and Uncle Kory Foundation Announce Partnership to Accelerate Brain Tumor Research
Jan 06, 2020
New Laser-Based Imaging System & Artificial Intelligence Algorithm, Used in Conjunction, Accurately Identify Brain Tumors
Dec 19, 2019
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
Dec 12, 2019
Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit
Dec 11, 2019
Biotech Advancements in the Immuno-Oncology Field for Pediatric and Adult Brain Tumors
Dec 11, 2019
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
Dec 11, 2019
Northwest Biotherapeutics (OTCQB; NWBO) Announces Presentation At Inaugural Glioblastoma Drug Development Summit
Dec 09, 2019
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit
Nov 26, 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Nov 25, 2019
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
Nov 25, 2019
DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM
Nov 25, 2019
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting
Nov 21, 2019
Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial
Nov 21, 2019
Cancer Drugs and New Therapies for Dangerous Brain Tumors Advancinghl2Financialnewsmedia.com News Commentary
Nov 20, 2019
Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results
Nov 20, 2019
CNS Pharmaceuticals Announces Attendance at the 24th Annual Meeting of the Society of Neuro-Oncology